STRATEGMED2/265503/3/NCBR/2015

The goal of this project is to develop an innovative therapeutic approach for cancer treatment – small molecule immunomodulators aimed at weakening the ability of tumors to escape immune surveillance. These selective inhibitors of enzymes that degrade arginine and tryptophan will be developed by an interdisciplinary consortium of industrial and academic partners conducting research in the fields of medicinal chemistry, biochemistry, biotechnology, nanotechnology, immunology, and medicine.
The expected outcome of the project is a fully developed lead compound – a clinical candidate with potential therapeutic applications for a broad range of cancers. Its identification will involve parallel discovery programs targeting several related enzymes, using drug delivery carriers in the form of nanoparticles. Achieving the project’s goal through synergistic collaboration between innovative biotech companies and leading academic and clinical centers will significantly enhance the international competitiveness of Polish science and the biomedical industry. If these new molecules pass through subsequent stages of clinical trials, they could have a global social and economic impact, providing a significant Polish contribution to the rapidly growing cancer immunotherapy market. Nowa terapia potencjalnie będzie wolna od licznych skutków ubocznych obecnych w obecnych terapiach przeciwnowotworowych, a tym samym będzie naprawdę zorientowana na pacjenta.

Project value: 2 440 000 002 zł

Funding value: 1 938 000,00 zł